title: LUX-Lung: determining the best EGFR inhibitor in NSCLC?
authors.affiliation: Division of Medical Oncology, SG Moscati Hospital, 83100-Avellino, Italy. Electronic address: arossi_it@yahoo.it.
authors.forename: Antonio
authors.initials: A
authors.lastname: Rossi
authors.affiliation: Department of Oncology, University of Turin, AOU San Luigi Gonzaga, Orbassano, Turin, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077716:Afatinib; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009154:Mutation / Q000235:genetics*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D011799:Quinazolines; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors